BOULDER, Colo., April 26, 2016 /PRNewswire/ -- Array
BioPharma Inc. (Nasdaq: ARRY) will report financial results
for the third quarter of fiscal 2016 and hold a conference call to
discuss those results on Tuesday, May
3, 2016. Ron Squarer, Chief Executive Officer, will
lead the call.
Date:
|
Tuesday, May 3,
2016
|
Time:
|
9:00 a.m. Eastern
Time
|
Toll-Free:
|
(844)
464-3927
|
Toll:
|
(765)
507-2598
|
Pass
Code:
|
86078064
|
Webcast, including
Replay and Conference Call
Slides: http://edge.media-server.com/m/p/stxvbem8
|
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Five registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162), encorafenib (LGX818) and selumetinib
(AstraZeneca). For more information on Array, please go to
www.arraybiopharma.com.
CONTACT:
|
Tricia
Haugeto
|
|
Array BioPharma
Inc.
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2016-on-may-3-2016-300257649.html
SOURCE Array BioPharma Inc.